ÂÜÀòÂÒÂ×

Paul joined Ampersand as an Operating Partner in 2018 and currently serves as a Chairman of the Board of MedPharm. Paul was previously the CEO and President of Renaissance Topicals Division and DPT Laboratories, which were both sold to Mylan in 2016. During his time at DPT, Paul was instrumental in the start-up and growth of Healthpoint Biologics, which sold to Smith & Nephew in 2011, and Coria, which sold to Valeant in 2008. Paul also spent time at Johnson & Johnson where he led an initiative to enter and expand operations in China. Paul holds a B.A. from the University of Texas at El Paso and a M.B.A from Southern Methodist University.